HAUVERDEEP: Effects of a Classic High-frequency rTMS Treatment Versus a Deep rTMS Treatment

Sponsor
Centre Hospitalier Henri Laborit (Other)
Overall Status
Recruiting
CT.gov ID
NCT04956016
Collaborator
(none)
152
1
2
38.3
4

Study Details

Study Description

Brief Summary

The main objective is to demonstrate that dTMS is more efficient than high frequency rTMS with a conventional coil.

The patient will receive treatment arm A or B :
Arm A : classic rTMS treatment (use of the 8-shaped coil) and standard therapy Arm B:

treatment with deep rTMS (use of the H-shaped coil (helmet)) and standard therapies.

20 rTMS sessions are planned (5 sessions per week) and 3 follow-up visits : at Day 30, Day 60 and Day 90.

Condition or Disease Intervention/Treatment Phase
  • Device: classic rTMS using the 8-shaped coil
  • Device: deep rTMS using the H1-shaped coil
N/A

Study Design

Study Type:
Interventional
Anticipated Enrollment :
152 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Single (Investigator)
Primary Purpose:
Treatment
Official Title:
Open-label Randomized Comparative Study of the Effects of a Classic High-frequency rTMS Treatment Versus a Deep rTMS Treatment in the Management of Resistant Depression
Actual Study Start Date :
Aug 23, 2021
Anticipated Primary Completion Date :
Nov 1, 2024
Anticipated Study Completion Date :
Nov 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: classic rTMS treatment

Arm A: classic rTMS treatment (use of the 8-shaped coil) and standard therapy

Device: classic rTMS using the 8-shaped coil
20 rTMS sessions are planned (5 sessions per week)

Active Comparator: treatment with deep rTMS

Arm B: treatment with deep rTMS (use of the H1-shaped coil (helmet)) and standard therapies

Device: deep rTMS using the H1-shaped coil
20 rTMS sessions are planned (5 sessions per week)

Outcome Measures

Primary Outcome Measures

  1. A 50% change of MADRS score [Day 60]

    The main objective is to demonstrate that dTMS is more efficient than high frequency rTMS with a conventional coil. Modification of the MADRS score compared to baseline score. MADRS stands for Montgomery-Asberg Depression Rating Scale. It is used to measure the severity of depressive episodes in patients with mood disorders. The questionnaire includes questions on the following symptoms 1. Apparent sadness 2. Reported sadness 3. Inner tension 4. Reduced sleep 5. Reduced appetite 6. Concentration difficulties 7. Lassitude 8. Inability to feel 9. Pessimistic thoughts 10. Suicidal thoughts and each item yields a score of 0 to 6. The overall score ranges from 0 to 60. A score from 0 to 6 being normal/symptom absent and a score >34 being severe depression.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Volunteer subjects over 18 years old

  • Having signed a free and informed consent

  • Having a diagnostic of caracterised depressive episod recurrent or isolated according to DSM IV criteria (A.P.A 1994).

  • Having an antidepressant treatment not modified since 3 weeks

  • Score to MADRS scale ≥ 21

  • Subject affiliated to a social security regimen

Exclusion Criteria:
  • Depression with psychotic caracteristics

  • Co-morbid diagnosis according to axis I (DSM IV) of schizophrenia, dependence (or abuse) on alcohol and / or another substance (lifetime)

  • Patient who has already undergone seismotherapy for current episode and non-responder to this treatment

  • Patient hospitalized under duress or under legal protection (guardianship, curatorship)

  • Patient with a high risk of suicide (item 10 of MADRS > 4) in the absence of hospitalization.

  • Contra-indication for IRM exam or rTMS : personnal history of comitial crisis, of neurological or neurochirurgical pathologies, metallic prosthetic material or foreign body (pacemaker, intraoculare ferromagnetic material, implanted cardiac defibrillator, cochlear implant, metal clip

  • Pregnancy

  • Simultaneous participation to another interventionnal study

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre Hospitalier Henri Laborit Poitiers France

Sponsors and Collaborators

  • Centre Hospitalier Henri Laborit

Investigators

  • Principal Investigator: Ghina HARIKA-GERMANEAU, Dr, Centre Hospitalier Henri Laborit

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Hospitalier Henri Laborit
ClinicalTrials.gov Identifier:
NCT04956016
Other Study ID Numbers:
  • 2021-A00796-35
First Posted:
Jul 9, 2021
Last Update Posted:
Dec 2, 2021
Last Verified:
Nov 1, 2021
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Dec 2, 2021